NCT07084584View on ClinicalTrials.gov

An Open-label, Dose-Escalation and Dose-Expansion Study of GB3226 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

184

Participants

Timeline

Start Date

June 10, 2026

Primary Completion Date

June 10, 2029

Study Completion Date

October 10, 2029

Conditions
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Interventions
DRUG

GB3226

GB3226: Dual inhibitor of ENL-YEATS and FLT3 pathways Administration: Oral, daily dosing in 28-day cycles

Sponsors

Lead Sponsor

Galecto Biotech AB
All Listed Sponsors
lead

Galecto Biotech AB

INDUSTRY